Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rollover Study of Itacitinib for Participants from Prior Incyte Itacitinib Trials
2022-501661-47-00Phase 2Completed
- Sponsor
- Incyte
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of itacitinib in myelofibrosis (MF), Bronchiolitis Obliterans Syndrome (BOS) and chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Primary endpoint: Safety (adverse events and serious adverse events). Started May 2023; status: completed.
02
Drugs
itacitinib
03
Conditions
myelofibrosis (MF)Bronchiolitis Obliterans Syndrome (BOS)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2022-501661-47-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501661-47-00.